Kanut Laoharawee

Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing

Kanut Laoharawee, Russell C. DeKelver, Kelly M. Podetz-Pedersen et al. · Molecular Therapy · 2018 · 119 citations · Full text

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease

Matthew J. Johnson, Kanut Laoharawee, Walker S. Lahr et al. · Scientific Reports · 2018 · 79 citations · Full text

ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome

Li Ou, Russell C. DeKelver, Michelle Rohde et al. · Molecular Therapy · 2018 · 78 citations · Full text

In Vivo Gene Therapy, Genetics, Immunology +22

Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System–Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer

Kanut Laoharawee, Kelly M. Podetz-Pedersen, Tam T. T. N. Nguyen et al. · Human Gene Therapy · 2017 · 48 citations

PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma

Branden A. Smeester, Nicholas J. Slipek, Emily J. Pomeroy et al. · Bone · 2020 · 33 citations

Oncology, Reduces Tumor Growth, Oncogenic Agent +7